Black Diamond Therapeutics
Black Diamond Therapeutics

Financials • Black Diamond Therapeutics

BDTX

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2017
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2018
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2019
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2020
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2021
0
-124
-123
0%
L
196
L
-210
-
-114
-3
1
-117
0
0
-
-
12/2022
0
-92
-12
0%
L
116
L
-123
-
-97
-0
0
-97
0
0
-
-
12/2023
0
-87
-12
0%
L
117
L
-131
-
-76
-0
72
-76
0
0
-
-
12/2024
0
-82
-12
0%
L
83
L
-99
-
-73
0
26
-73
0
0
-
-
12/2025
70
12
01
32%
0.39
112
20%
-129
-
23
0
-0
23
0
0
-
-

To see all financials—including updated, you must be Premium.